Source: International Congress 2016 – Late-breaking translational research in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Malamati Vreka (Munich, Germany), Malamati Vreka, Ioannis Lilis, Maria Papageorgopoulou, Magda Spella, Antonia Marazioti, Anastasios D. Giannou, Theodora Agalioti, Georgios T. Stathopoulos. LSC Abstract – A requirement for IKKa in lung adenocarcinoma. Eur Respir J 2016; 48: Suppl. 60, 1524

Member's Comments

No comment yet.

Related content which might interest you: MEK5 promotes lung adenocarcinoma Source: Eur Respir J, 53 (2) 1801327; 10.1183/13993003.01327-2018 Year: 2019 A requirement for IKKa in lung adenocarcinoma Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 LSC - 2018 - A requirement for mast cells in lung adenocarcinoma Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Telomerase activation in a model of lung adenocarcinoma Source: Eur Respir J 2006; 27: 1175-1182 Year: 2006 PP131 – Macrophages in lung adenocarcinoma Source: ERS Lung Science Conference 2021 Year: 2021 Prognostic significance of the expressions of Axl and/or Gas6 in patients with completely resected lung adenocarcinoma Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 CREB signaling in KRAS-driven lung adenocarcinoma Source: ERS Lung Science Conference 2017 Year: 2017 Telomerase activation in adenocarcinoma-bronchioloalveolar carcinoma Source: Eur Respir J 2006; 27: 1079-1081 Year: 2006 LSC - 2017 - CREB signaling in KRAS-driven lung adenocarcinoma Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017 Synchronous primary lung cancer with three separate tumors Source: Annual Congress 2007 - Lung neoplasms Year: 2007 Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Synchronous lung adenocarcinoma and intrapulmonary thymoma: A rare entity Source: International Congress 2016 – Open problems in thoracic surgery Year: 2016 Increased sirtuin expression in patient with lung squamous cell carcinoma co-morbid with COPD Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification Source: Eur Respir J 2011; 38: 239-243 Year: 2011 Myeloid derived suppressor cells in the crosstalk between COPD and lung cancer Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011 Improving standards in flexible bronchoscopy for lung cancer Source: Eur Respir J 2011; 37: 895-901 Year: 2011 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013